Page last updated: 2024-12-08
matteucinol
Description
matteucinol: isolated from leaves of Rhododendron simsii; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
matteucinol : A dihydroxyflavanone that is (2S)-flavanone with hydroxy groups at positions 5 and 7, methyl groups at positions 6 and 8 and a methoxy group at position 4'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Rhododendron | genus | A plant genus of the family ERICACEAE.[MeSH] | Ericaceae | The heath plant family of the order Ericales, subclass Dilleniidae, class Magnoliopsida that are generally shrubs or small trees. Leaves are alternate, simple, and leathery; flowers are symmetrical with a 4- or 5-parted corolla of partly fused petals.[MeSH] |
Cross-References
Synonyms (13)
| Synonym |
|---|
| matteucinol |
| 489-38-3 |
| (2s)-5,7-dihydroxy-2-(4-methoxyphenyl)-6,8-dimethyl-2,3-dihydrochromen-4-one |
| 4'-methylfarrerol |
| 4h-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-6,8-dimethyl-, (s)- |
| (2s)-5,7-dihydroxy-4'-methoxy-6,8-dimethylflavanone |
| (2s)-5,7-dihydroxy-2-(4-methoxyphenyl)-6,8-dimethyl-2,3-dihydro-4h-chromen-4-one |
| CHEBI:76323 |
| Q27145883 |
| bdbm50278272 |
| DTXSID60964134 |
| 5,7-dihydroxy-2-(4-methoxyphenyl)-6,8-dimethyl-2,3-dihydro-4h-1-benzopyran-4-one |
| CHEMBL4164421 , |
Roles (2)
| Role | Description |
|---|
| radical scavenger | A role played by a substance that can react readily with, and thereby eliminate, radicals. |
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| dihydroxyflavanone | Any hydroxyflavanone carrying two hydroxy substituents. |
| monomethoxyflavanone | Any methoxyflavanone that is flavanone substituted by a methoxy group. |
| 4'-methoxyflavanones | Any methoxyflavanone having a methoxy substituent located at position 4'. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | IC50 (µMol) | 25.2000 | 0.0005 | 0.9767 | 10.0000 | AID1502944 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (1)
Molecular Functions (2)
Ceullar Components (2)
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1502947 | Cytotoxicity against MDCK cells after 2 days by MTT assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10
| C-Methylated Flavonoid Glycosides from Pentarhizidium orientale Rhizomes and Their Inhibitory Effects on the H1N1 Influenza Virus. |
| AID1502945 | Inhibition of neuraminidase activity in H9N2 A/chicken/Korea/01210/2001 infected in MDCK cells using 4-MU-NANA as substrate pretreated for 30 mins followed by substrate addition measured after 2 hrs by fluorescence assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10
| C-Methylated Flavonoid Glycosides from Pentarhizidium orientale Rhizomes and Their Inhibitory Effects on the H1N1 Influenza Virus. |
| AID1502944 | Inhibition of neuraminidase activity in Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells using 4-MU-NANA as substrate pretreated for 30 mins followed by substrate addition measured after 2 hrs by fluorescence assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10
| C-Methylated Flavonoid Glycosides from Pentarhizidium orientale Rhizomes and Their Inhibitory Effects on the H1N1 Influenza Virus. |
| AID1502946 | Antiviral activity against Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by MTT assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10
| C-Methylated Flavonoid Glycosides from Pentarhizidium orientale Rhizomes and Their Inhibitory Effects on the H1N1 Influenza Virus. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.15 (24.57) | | Research Supply Index | 2.30 (2.92) | | Research Growth Index | 4.45 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |